Overview

• Amgen delivered second-quarter revenue of $9.2 billion, up 9% year-on-year; adjusted earnings per share rose 21% to $6.02, beating consensus forecasts.
• The company raised its full-year outlook to adjusted earnings per share of $20.20 to $21.30; revenue guidance increased to $35 billion to $36 billion.
• Repatha sales rose 31% to $696 million; Prolia sales fell 4% to $1.1 billion under pressure from biosimilar competition.
• Operating expenses rose 8% year-on-year; research and development costs jumped 18% to fund MariTide trials and biosimilar development.
• Shares fell 5.1% to $284.97 following the results, reflecting investor caution ahead of fourth-quarter readouts from two mid-stage MariTide studies.